secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001683168-26-001413
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals appoints Lynne Kelley as CMO; former CMO Sandra Silberman departs with severance
--------------------------------------------------------------------------------

- Lynne Kelley appointed CMO effective March 2, 2026; base salary $450K, target bonus 40%.
- Initial RSU grant of 9,500 shares; vests 25% at 6 months, 25% at 12 months, balance quarterly.
- Severance: 6 months base salary plus prorated bonus and accelerated equity if terminated without cause.
- Former CMO Sandra Silberman receives 3 months base salary severance under separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316826001413/0001683168-26-001413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316826001413/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer